Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology · Renovascular Hypertension

Modern Treatment Strategies: From Medication to Procedures

At a Glance

For most people with renovascular hypertension caused by atherosclerosis, the best treatment is a combination of blood pressure medications and lifestyle changes. Stents and balloon angioplasty are usually reserved for high-risk patients or those with fibromuscular dysplasia.

The way doctors treat renovascular hypertension (RVH) has changed dramatically over the last decade. While it was once common to automatically “fix” a narrowed kidney artery with a stent, modern research has shown that for many patients, the best treatment is not a procedure, but high-quality medical and lifestyle management [1].

The ARAS Strategy: Medical Therapy First

If your narrowing is caused by atherosclerosis (ARAS), your treatment plan will likely focus on Optimal Medical Therapy (OMT) [2]. This typically includes:

  1. RAAS Inhibitors: Medications like ACE inhibitors or ARBs that block the hormones causing your high blood pressure [1].
  2. Statins: Drugs to lower cholesterol and stabilize the plaque in your arteries [3].
  3. Antiplatelet Therapy: Often a daily low-dose aspirin to prevent blood clots [1].
  4. Lifestyle Modifications: Because ARAS is driven by the same factors as heart disease, you have significant control over slowing its progression. Quitting smoking, eating a low-sodium diet to manage fluid retention, and engaging in regular exercise are critical steps [4].

Why the shift away from stenting? Two massive clinical trials, known as CORAL and ASTRAL, proved that for the vast majority of ARAS patients, adding a stent did not reduce the risk of heart attacks, strokes, or kidney failure any better than medication alone [5][6][7]. Because stenting carries its own risks, it is no longer the “default” choice [8].

When a Stent IS Necessary for ARAS

While medication is the first choice for stable patients, there are critical “high-risk” scenarios where a procedure (revascularization) becomes a necessary, often life-saving intervention [9][10]:

  • Pickering Syndrome: Recurring episodes of flash pulmonary edema (sudden, severe fluid in the lungs) [11][12].
  • Refractory Hypertension: Blood pressure that remains dangerously high even when taking several different medications [13].
  • Rapid Kidney Decline: A sudden, unexplained loss of kidney function that threatens to lead to dialysis [14][15].

The FMD Strategy: Balloon Angioplasty

The approach for Fibromuscular Dysplasia (FMD) is different because the underlying biology is different [16]. Since FMD is a structural issue in the artery wall rather than a fatty buildup, it often responds exceptionally well to percutaneous transluminal renal angioplasty (PTRA) [17].

During this procedure, a doctor uses a small balloon to widen the narrowed section of the artery [18]. In many FMD cases, a stent is not required, and the procedure can significantly lower blood pressure or even cure the condition entirely, allowing some patients to stop taking blood pressure pills altogether [16][18]. However, FMD can sometimes return, so regular follow-up imaging is essential [19].

Common questions in this guide

Why is medication often recommended instead of a stent for renovascular hypertension?
Clinical trials have shown that for most stable patients with atherosclerosis, adding a stent does not lower the risk of heart attacks or kidney failure better than medication alone. Since stenting has its own risks, doctors usually start with optimal medical therapy.
When is a stent necessary for treating kidney artery narrowing?
A stent or revascularization procedure is typically reserved for high-risk situations. These include having sudden severe fluid in the lungs, blood pressure that stays dangerously high despite taking multiple medications, or a rapid, unexplained loss of kidney function.
How is fibromuscular dysplasia (FMD) treated differently than atherosclerosis?
Because FMD is a structural issue in the artery wall rather than a fatty plaque buildup, it often responds very well to balloon angioplasty. This procedure widens the narrowed artery, often without needing a permanent stent, and can significantly lower or even cure high blood pressure.
What medications are used in Optimal Medical Therapy for renovascular hypertension?
Treatment typically includes RAAS inhibitors to block hormones causing high blood pressure, statins to lower cholesterol and stabilize plaque, and antiplatelet drugs like aspirin to prevent blood clots. Lifestyle changes like quitting smoking and eating a low-sodium diet are also essential.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the results of the CORAL and ASTRAL trials, why is a stent recommended for me instead of just medical therapy?
  2. 2.Am I currently experiencing any 'high-risk' symptoms, like flash pulmonary edema, that make a procedure necessary right now?
  3. 3.If I have FMD, what is the likelihood that balloon angioplasty could 'cure' my high blood pressure?
  4. 4.If we choose 'Medical Therapy First,' what specific goals are we looking for to know it's working?
  5. 5.What are the risks of a stent or angioplasty given my age and current kidney function?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Renal artery stenosis.

    Safian RD

    Progress in cardiovascular diseases 2021; (65()):60-70 doi:10.1016/j.pcad.2021.03.003.

    PMID: 33745915
  2. 2

    The 'Ten Commandments' of 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases.

    Aboyans V, Ricco JB

    European heart journal 2018; (39(9)):722 doi:10.1093/eurheartj/ehy045.

    PMID: 29506063
  3. 3

    Optimal medical therapy, clinical outcome and its predictors in patients with acute coronary syndrome after discharge with secondary prevention medications at University of Gondar Comprehensive Specialized Hospital, North West Ethiopia, 2023: A retrospective follow-up study.

    Geremew GW, Alemayehu TT, Bekalu AF, et al.

    BMC cardiovascular disorders 2024; (24(1)):533 doi:10.1186/s12872-024-04199-x.

    PMID: 39363265
  4. 4

    Atherosclerotic Renal Artery Stenosis.

    Schoepe R, McQuillan S, Valsan D, Teehan G

    Advances in experimental medicine and biology 2017; (956()):209-213 doi:10.1007/5584_2016_89.

    PMID: 27873231
  5. 5

    Emerging Paradigms in Chronic Kidney Ischemia.

    Eirin A, Textor SC, Lerman LO

    Hypertension (Dallas, Tex. : 1979) 2018; (72(5)):1023-1030 doi:10.1161/HYPERTENSIONAHA.118.11082.

    PMID: 30354824
  6. 6

    Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.

    Tuttle KR, Dworkin LD, Henrich W, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2016; (11(7)):1180-1188 doi:10.2215/CJN.10491015.

    PMID: 27225988
  7. 7

    Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis.

    Chen Y, Pan H, Luo G, et al.

    The Journal of international medical research 2021; (49(1)):300060520983585 doi:10.1177/0300060520983585.

    PMID: 33478308
  8. 8

    Quality of life effects of renal artery stenting versus medical therapy for atherosclerotic renal-artery stenosis: results from the randomized CORAL trial.

    Arnold SV, Wang K, Kirtane AJ, et al.

    European heart journal. Quality of care & clinical outcomes 2025; (11(8)):1388-1395 doi:10.1093/ehjqcco/qcae087.

    PMID: 39402005
  9. 9

    Renal Artery Stenosis in the Patient with Hypertension: Prevalence, Impact and Management.

    Manaktala R, Tafur-Soto JD, White CJ

    Integrated blood pressure control 2020; (13()):71-82 doi:10.2147/IBPC.S248579.

    PMID: 32581575
  10. 10

    Acute cardiorenal decompensation in the setting of chronic renal artery stenosis treated with successful renal artery stenting. A case report.

    Ahmed N, Arriola-Montenegro J, Rashid S, et al.

    Archivos peruanos de cardiologia y cirugia cardiovascular 2025; (6(4)):269-273 doi:10.47487/apcyccv.v6i4.515.

    PMID: 41582939
  11. 11

    Pickering Syndrome: An Overlooked Renovascular Cause of Recurrent Heart Failure.

    Sanga V, Bertoli E, Crimì F, et al.

    Journal of the American Heart Association 2023; (12(19)):e030474 doi:10.1161/JAHA.123.030474.

    PMID: 37750563
  12. 12

    Pickering syndrome in a patient with a single kidney: role of renal artery stenting.

    Malas A, Ali AE, Al-Balas A, Almehmi A

    Radiology case reports 2023; (18(8)):2618-2620 doi:10.1016/j.radcr.2023.04.063.

    PMID: 37273730
  13. 13

    Simultaneous Bilateral Renal Revascularization in an Elderly Patient With Recurrent Flash Pulmonary Edema: A Case Report.

    Teixeira da Matta Flora Neto A, Valdisser Jaculi Teixeira Bento G, Couto de Oliveira Azevedo L, et al.

    Cureus 2026; (18(1)):e101079 doi:10.7759/cureus.101079.

    PMID: 41664771
  14. 14

    Revascularization in a Time After CORAL.

    Dionne AR, Columbo JA, Block C, Hopley CW

    JACC. Case reports 2024; (29(17)):102501 doi:10.1016/j.jaccas.2024.102501.

    PMID: 39359498
  15. 15

    Atherosclerotic renovascular disease and cardiovascular risk: new concepts.

    Januszewicz A, Januszewicz M, Prejbisz A, et al.

    Polish archives of internal medicine 2022; (132(12)) doi:10.20452/pamw.16384.

    PMID: 36533812
  16. 16

    Resistant Renovascular Hypertension in Youth: Fibromuscular Dysplasia or Takayasu Arteritis?

    Michalczewska A, Pytlos J, Żyłkowski J, et al.

    The American journal of case reports 2025; (26()):e945673 doi:10.12659/AJCR.945673.

    PMID: 39834060
  17. 17

    Segmental low-density area on contrast-enhanced CT is a possible clue to diagnosing branch artery fibromuscular dysplasia.

    Kiyohara Y, Hirose R, Kawamata H, et al.

    Endocrinology, diabetes & metabolism case reports 2023; (2023(4)).

    PMID: 38006656
  18. 18

    Endovascular Treatment of Renal Artery Stenosis due to Fibromuscular Dysplasia - Is Stent Implantation Underused in this Circumstance?

    Edem E, Aksoy MN, Pabuccu MT, Tatlı E

    Heart views : the official journal of the Gulf Heart Association 2016; (17(2)):69-71 doi:10.4103/1995-705X.185118.

    PMID: 27512536
  19. 19

    Case report: Recurrence of hypertension after renal artery angioplasty due to the progression of focal renal fibromuscular dysplasia.

    Hong M, Kang Y, Xu J, Wang J

    Frontiers in cardiovascular medicine 2022; (9()):1008308 doi:10.3389/fcvm.2022.1008308.

    PMID: 36465456

This page provides general information on modern renovascular hypertension treatment strategies. Always consult your nephrologist or cardiologist for personalized medical advice regarding your medication management or the need for a procedure.

Get notified when new evidence is published on benign renovascular hypertension.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.